scispace - formally typeset
Book ChapterDOI

Traditional Chinese Medicines as Possible Remedy Against SARS-CoV-2

TLDR
Wang et al. as mentioned in this paper proposed to use traditional Chinese medicine (TCM) against SARS-CoV in the third edition of COVID-19 Treatment Guidelines (2020) published in January 2019.
Abstract
Keeping in view the pandemic situation and whose recommendations to search antiviral medicines, biologists, pathologists, and microbiologists started working on that Chinese government has recommended therapeutic application of traditional Chinese medicine (TCM) against COVID-19 in the third edition of COVID-19 Treatment Guidelines (2020) published in January From the day onward, hundreds of herbs have been practiced all over China This chapter has been planned to compile existing information for future utilization of TCM all over the world with better understanding and minimal chances of side effects For well understanding of TCM as reliable treatment (for COVID-19), it is aimed to pool data of TCM from its history of usage against other viruses and against related viruses of SARS-CoV, collection of the data regarding case studies with positive outcomes, detailed pool of knowledge about most practiced (approved/proposed) decoctions, frequently used components of these decoctions, their active ingredients, possible mechanism to inhibit viruses, similarity of SARS-CoV with SARS-CoV-2, and possibility to treat COVID-19 with antiviral drugs previously used against SARS-CoV Additional relevant meta-analyses have been reviewed that may guide about practical implementation of these TCM in the future round the globe

read more

Citations
More filters

Investigation on mechanism and active components of Shufeng Jiedu Capsule in treatment of COVID-19 based on network pharmacology and molecular docking/ 基于网络药理学与分子对接方法的疏风解毒胶囊治疗新型冠状病毒肺炎(COVID-19)的作用机制与活性成分研究

TL;DR: The compounds in Shufeng Jiedu Capsule can regulate the signaling pathway of human cytomegalov virus infection, Kaposi's sarcoma associated herpesvirus infection, IL-17 signaling pathway, small cell lung cancer, etc. to treat COVID-19 by binding with SARS-CoV-2 3CL hydrolase and ACE2.
Proceedings ArticleDOI

Drug Repurposing For SARS-COV-2 Using Molecular Docking

TL;DR: In this article , a leading drug candidate Cepharanthine (CEP) has shown better results and effectiveness than recently used antiviral drug candidates such as Favipiravir, IDX184, Remedesivir, Ribavirin and etc.
Proceedings ArticleDOI

Drug Repurposing For SARS-COV-2 Using Molecular Docking

TL;DR: Cepharanthine potential therapeutic importance as a drug of choice in managing COVID-19 cases is analyzed and it is anticipated that proposed study would be beneficial for researchers and medical practitioners in handling SARS-CoV-2 and its variant related diseases.
References
More filters
Journal ArticleDOI

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

TL;DR: The epidemiological and clinical characteristics of novel coronavirus (2019-nCoV)-infected pneumonia in Wuhan, China, and hospital-associated transmission as the presumed mechanism of infection for affected health professionals and hospitalized patients are described.
Related Papers (5)